Valsts: Īrija
Valoda: angļu
Klimata pārmaiņas: HPRA (Health Products Regulatory Authority)
ROPINIROLE HYDROCHLORIDE
Glenmark Generics (Europe) Ltd
0.5 Milligram
Film Coated Tablet
2010-11-12
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Ropinirole Glenmark 0.5mg film coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains ropinirole hydrochloride equivalent to 0.5 mg of ropinirole. Excipient: 72.68 mg lactose (as lactose monohydrate and lactose anhydrous) For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-Coated Tablet. Pale Yellow to Yellow, circular, bevelled edged, biconvex film coated tablets with ‘254’ debossed on one side and ‘G’ on the other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of Parkinson's disease under the following conditions: Initial treatment as monotherapy, in order to delay the introduction of levodopa In combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur ("end of dose" or "on-off" type fluctuations) Or For the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Oral use. _Idiopathic Parkinson’s Disease:_ Adults Individual dose titration against efficacy and tolerability is recommended. “Ropinirol Glenmark” should be taken three times a day, preferably with meals to improve gastrointestinal tolerance. _Treatment initiation_ The initial dose of ropinirole should be 0.25 mg three times daily for 1 week. Thereafter, the dose of ropinirole can be increased in 0.25 mg three times daily increments, according to the following regimen: IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 28/09/2011_ _CRN 2098133_ _page number: 1_ _Therapeutic regimen_ After the init Izlasiet visu dokumentu